Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ (3,440) $ (2,451)
General and administrative (3,933) (3,396)
Total operating expenses (7,373) (5,847)
Operating loss (7,373) (5,847)
Interest expense, net (1,039) (2,952)
Adjustments to fair value of derivatives 5,177 (90,103)
Other income, net 162 41
Total other income / (expense), net 4,300 (93,014)
Loss before income taxes (3,073) (98,861)
Income tax expense (427) (60)
Net loss and comprehensive loss (3,500) (98,921)
Net loss attributable to ordinary shareholders $ (3,500) $ (98,921)
Net loss per share attributable to ordinary shareholders - basic and diluted $ (0.02) $ (0.81)
Weighted average ordinary shares outstanding - basic and diluted 182,901,530 121,549,083